-
1Academic Journal
Authors: Lyons, A.R.M.
Source: Наука и здравоохранение. :128-132
Subject Terms: hypercholesterolemia, familial hypercholesterolemia, қан айналымы жүйесінің аурулары, дислипидемия, registry, 3. Good health, cardiovascular diseases, семейная гиперхолестеринемия, отбасылық гиперхолестеринемия, регистр, yslipidemia, гиперхолестеринемия, тіркелім, болезни системы кровообращения
-
2Academic Journal
Authors: L. F. Galimova, D. I. Sadykova, I. V. Leontyeva, E. S. Slastnikova, Ch. D. Khaliullina, K. R. Salahova, Л. Ф. Галимова, Д. И. Садыкова, И. В. Леонтьева, Е. С. Сластникова, Ч. Д. Халиуллина, К. Р. Салахова
Contributors: This work perfomed under grant of Kazan State Medical University and supported by Government program «Pryority-2030»., Исследование выполнено за счет средств гранта Федерального государственного бюджетного учреждения высшего образования "Казанский государственный медицинский университет" Минздрава России, при финансовой поддержке Государственной программы «Приоритет-2030».
Source: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 70, № 5 (2025); 157-167 ; Российский вестник перинатологии и педиатрии; Том 70, № 5 (2025); 157-167 ; 2500-2228 ; 1027-4065
Subject Terms: атеросклероз, familial hypercholesterolemia, dispensary observation, vascular remodeling, atherosclerosis, семейная гиперхолестеринемия, диспансерное наблюдение, сосудистое ремоделирование
File Description: application/pdf
Relation: https://www.ped-perinatology.ru/jour/article/view/2272/1642; Российский статистический ежегодник 2022: статистический сборник. Росстат. М., 2022; 691 https://rosstat.gov.ru/storage/mediabank/Ejegodnik_2022.pdf. ссылка активна на 10.06.2025; Кухарчук В.В., Ежов М.В., Сергиенко И.В., Арабидзе Г.Г., Бубнова М.Г., Балахонова Т.В. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020; 1(38): 7–42. DOI:10.34687/2219-8202.JAD.2020.01.0002; Majithia A.R., Altshuler D., Hirschhorn J.N. Williams Textbook of Endocrinology (Thirteenth Edition). Philadelphia: Elsivier, 2016; 1916. DOI:10.1016/C2013-0-15980-6; Gorabi A.M., Kiaie N., Hajighasemi S., Banach M., Penson P.E., Jamialahmadi T., Sahebkar A. Statin-Induced Nitric Oxide Signaling: Mechanisms and Therapeutic Implications. J Clin Med. 2019; 8(12): 2051. DOI:10.3390/jcm8122051; Wiegman A., Gidding S.S., Watts G.F., Chapman M.J., Ginsberg H.N., Cuchel M. et al. European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015; 36(36): 2425–2437. DOI:10.1093/eurheartj/ehv157; Чубыкина У.В., Афанасьева О.И., Тмоян Н.А., Ежов М.В. Программы наблюдения и скрининга больных с семейной гиперхолестеринемией. Атеросклероз и дислипидемии. 2020; 2(39): 43–48. DOI:10.34687/2219-8202.JAD.2020.02.0006; Dharmayat K.I., Vallejo-Vaz A.J., Stevens C.A.T., Brandts J.M., Lyons A.R.M., Groselj U., et al. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study. The Lancet 2024; 403: 55–66. DOI:10.1016/S0140–6736(23)01842–1; Catapano A.L., Graham I., De Backer G., Wiklund O., Chapman M.J., Drexel H., et al. ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016; 37(39): 2999–3058. DOI:10.1093/eurheartj/ehw272; Ежов М.В., Бажан С.С., Ершова А.И., Мешков А.Н., Соколов А.А., Кухарчук В.В. и др. Клинические рекомендации по семейной гиперхолестеринемии. Атеросклероз. 2019; 15(1): 58–98.; Neunteufl T., Heher S., Katzenschlager R., Wölfl G., Kostner K., Maurer G., Weidinger F. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol. 2000; 86(2): 207–210. DOI:10.1016/s0002-9149(00)00857-2; Suhett L.G., Hermsdorff H.M., Rocha N.P., Silva M.A., Filgueiras M.S., Milagres L.C. et al. Increased C-Reactive Protein in Brazilian Children: Association with Cardiometabolic Risk and Metabolic Syndrome Components (PASE Study). Cardiol Res Pract. 2019; 2019: 3904568. DOI:10.1155/2019/3904568; Anderson T.J., Grégoire J., Pearson G.J., Barry A.R., Couture P., Dawes M. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can J Cardiol. 2016; 32(11): 1263–1282. DOI:10.1016/j.cjca.2016.07.510; Lampsas S., Xenou M., Oikonomou E., Pantelidis P., Lysandrou A., Sarantos S. Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment. Molecules. 2023; 28(3): 969. DOI:10.3390/molecules28030969
-
3Academic Journal
Authors: И.С. Захарова, А.И. Шевченко, С.М. Закиян
Source: Письма в Вавиловский журнал генетики и селекции, Vol 10, Iss 1, Pp 5-14 (2024)
Subject Terms: семейная гиперхолестеринемия, атеросклероз, рецептор липопротеинов низкой плотности, клеточные модели, индуцированные плюрипотентные стволовые клетки, эндотелий, Genetics, QH426-470
File Description: electronic resource
-
4Academic Journal
Authors: Marushko, T.V., Mitchenko, O.I., Holubovska, Yu.Ye.
Source: Здоров'я суспільства-Zdorov'a suspil'stva; Том 6, № 4 (2017); 172-178
Health of Society; Том 6, № 4 (2017); 172-178
Здоровье общества-Zdorov'a suspil'stva; Том 6, № 4 (2017); 172-178Subject Terms: атеросклероз, дисліпідемії, сімейна гіперхолестеринемія, діти, дислипидемии, семейная гиперхолестеринемия, дети, atherosclerosis, dyslipidemia, familial hypercholesterolemia, children, 3. Good health
File Description: application/pdf
-
5Academic Journal
Authors: D. I. Sadykova, E. S. Slastnikova, L. F. Galimova, E. I. Shagimardanova, R. R. Nigmatullina, K. R. Salakhova, Ch. D. Khaliullina, Д. И. Садыкова, Е. С. Сластникова, Л. Ф. Галимова, Е. И. Шагимарданова, Р. Р. Нигматуллина, К. Р. Салахова, Ч. Д. Халиуллина
Source: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 69, № 5 (2024); 75-81 ; Российский вестник перинатологии и педиатрии; Том 69, № 5 (2024); 75-81 ; 2500-2228 ; 1027-4065
Subject Terms: атеросклероз, familial hypercholesterolemia, apolipoprotein E, hypercholesterolemia, atherosclerosis, семейная гиперхолестеринемия, аполипопротеин Е, гиперхолестеринемия
File Description: application/pdf
Relation: https://www.ped-perinatology.ru/jour/article/view/2068/1534; Dharmayat K.I., Vallejo-Vaz A.J., Stevens C.A.T., Brandts J.M., Lyons A.R.M., Groselj U. et al. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study. The Lancet 2024; 403: 55—66. DOI:10.1016/S0140–6736(23)01842–1; Ежов М.В., Бажан С.С., Ершова А.И., Мешков А.Н., Соколов А.А., Кухарчук В.В. и др. Клинические рекомендации по семейной гиперхолестеринемии. Атеросклероз 2019; 15(1): 58–98.; Simonen P., Öörni K., Sinisalo J., Strandberg T.E., Wester I., Gylling H. High cholesterol absorption: A risk factor of atherosclerotic cardiovascular diseases? Atherosclerosis 2023; 376: 53–62. DOI:10.1016/j.atherosclerosis.2023.06.003; Fiorentino R., Chiarelli F. Treatment of Dyslipidaemia in Children. Biomedicines 2021; 9, 1078. DOI:10.3390/biomedicines9091078; Elkins C., Fruh S., Jones L., Bydalek K. Clinical Practice Recommendations for Pediatric Dyslipidemia. J Pediatr Health Care 2019; 33(4): 494–504. DOI:10.1016/j.pedhc.2019.02.009; Alagarsamy J., Jaeschke A., Hui D.Y. Apolipoprotein E in Cardiometabolic and Neurological Health and Diseases. Int J Mol Sci 2022; 23: 9892. DOI:10.3390/ijms23179892; Садыкова Д.И., Зиатдинов А.И., Сенек С.А., Гусева Н.Э., Галимова Л.Ф., Сластникова Е.С. и др. Опыт организации медицинской помощи детям с нарушениями липидного обмена на примере работы Центра липидологии Детской республиканской клинической больницы в Республике Татарстан. Атеросклероз и дислипидемии 2021; 1(42): 52–58.; Grönroos P., Raitakari O.T., Kähönen M., Hutri-Kähönen N., Marniemi J., Viikari J. et al. Influence of apolipoprotein E polymorphism on serum lipid and lipoprotein changes: a 21-year follow-up study from childhood to adulthood. The Cardiovascular Risk in Young Finns Study. Clin Chem Lab Med 2007; 45(5): 592–598. DOI:10.1515/CCLM.2007.116
-
6Academic Journal
Authors: Marushko, T.V., Mitchenko, O.I., Holubovska, Yu.Ye.
Source: Здоров'я суспільства-Zdorov'a suspil'stva; Том 7, № 1 (2018); 43-50
Health of Society; Том 7, № 1 (2018); 43-50
Здоровье общества-Zdorov'a suspil'stva; Том 7, № 1 (2018); 43-50Subject Terms: атеросклероз, дисліпідемії, сімейна гіперхолестеринемія, діти, дислипидемии, семейная гиперхолестеринемия, дети, atherosclerosis, dyslipidemia, familial hypercholesterolemia, children, 3. Good health
File Description: application/pdf
-
7Academic Journal
Source: Сучасна педіатрія. Україна; № 2(130) (2023): Сучасна педіатрія. Україна; 24-31
Modern Pediatrics. Ukraine; No. 2(130) (2023): Modern pediatrics. Ukraine; 24-31
Modern Pediatrics. Ukraine; № 2(130) (2023): Modern pediatrics. Ukraine; 24-31Subject Terms: фізична активність, здоровье, familial hypercholesterolemia, дислипидемия, dyslipidemia, качество жизни, связанное со здоровьем, physical activity, health, физическая активность, діти, дети, 3. Good health, дисліпідемія, health-related quality of life, семейная гиперхолестеринемия, children, сімейна гіперхолестеринемія, здоров'я, якість життя, пов'язана зі здоров'ям
File Description: application/pdf
Access URL: http://mpu.med-expert.com.ua/article/view/279293
-
8Academic Journal
Authors: Eşanu, V., Pîrţu, L.I., Pirtsu, L., Rodoman, I., Palii, I.
Source: Ziua bolilor rare
Subject Terms: child, семейная гиперхолестеринемия, familial hypercholesterolemia, ребёнок, screening, дислипидемия, dyslipidemia, скрининг
File Description: application/pdf
Access URL: https://ibn.idsi.md/vizualizare_articol/196578
-
9Academic Journal
Authors: Nikonov, A. A., Trunova, Y. A., Никонов, А. А., Трунова, Ю. А.
Source: Сборник статей
Subject Terms: HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, CHILDREN, DIAGNOSTICS, ГЕТЕРОЗИГОТНАЯ СЕМЕЙНАЯ ГИПЕРХОЛЕСТЕРИНЕМИЯ, ДЕТИ, ДИАГНОСТИКА
File Description: application/pdf
Relation: Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей VIII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 19-20 апреля 2023 г.; http://elib.usma.ru/handle/usma/14361
Availability: http://elib.usma.ru/handle/usma/14361
-
10Academic Journal
Authors: Dinara I. Sadykova, Karina R. Salakhova, Liliya F. Galimova, Eugeniya S. Slastnikova, Chulpan D. Khaliullina, Д. И. Садыкова, К. Р. Салахова, Л. Ф. Галимова, Е. С. Сластникова, Ч. Д. Халиуллина
Contributors: The study was carried out with the financial support of Kazan State Medical University, grant from the International research board for young scientists (recipient — K.R. Salakhova, 2022), Работа выполнена при финансовой поддержке Казанского государственного медицинского университета, грант Международного научного совета для молодых ученых (получатель — Салахова К.Р., 2022)
Source: Current Pediatrics; Том 22, № 3 (2023); 231-240 ; Вопросы современной педиатрии; Том 22, № 3 (2023); 231-240 ; 1682-5535 ; 1682-5527
Subject Terms: перспективные направления исследований, familial hypercholesterolemia, diagnostics, low-density lipoproteins, dyslipidemia, advanced research directions, семейная гиперхолестеринемия, диагностика, липопротеиды низкой плотности, дислипидемия
File Description: application/pdf
Relation: https://vsp.spr-journal.ru/jour/article/view/3223/1297; Cardiovascular diseases. In: World Health Organization: Official website. Available online: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1. Accessed on April 12, 2023.; Маль Г.С., Смахтина А.М. Вторичная гиперлипидемия: определение, фенотипы и индуцирующие факторы // Международный журнал сердца и сосудистых заболеваний. — 2021. — Т. 9. — № 32. — С. 43–51. — doi: https://doi.org/10.24412/2311-16232021-32-43-51; Thongtang N, Sukmawan R, Llanes EJB, Lee ZV. Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices. Preventive Medicine Reports. 2022;27:a101819. doi: https://doi.org/10.1016/j.pmedr.2022.101819; Концевая А.В., Баланова Ю.А., Имаева А.Э. и др. Экономический ущерб от гиперхолестеринемии на популяционном уровне в Российской Федерации // Рациональная фармакотерапия в кардиологии. — 2018. — Т. 14. — № 3. — С. 393–401. — doi: https://doi.org/10.20996/1819-6446-2018-14-3-393401; Садыкова Д.И., Лутфуллин И.Я. Первичная артериальная гипертензия и гипертрофия миокарда в детском и подростковом возрасте // Педиатрия. Журнал им. Г.Н. Сперанского. — 2009. — Т. 88. — № 5. — С. 16–21.; Vaduganathan M, Mensah GA, Turco JV, et al. The global burden of cardiovascular diseases and risk: a compass for future health. J Am Coll Cardiol. 2022;80(25):2361–2371. doi: https://doi.org/10.1016/j.jacc.2022.11.005; Gujral J, Gupta J. Pediatric Dyslipidemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available online: https://www.ncbi.nlm.nih.gov/books/NBK585106. Accessed on July 28, 2022.; McGill HC Jr, McMahan CA, Malcom GT, et al. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. The PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol. 1997; 17(1):95–106. doi: https://doi.org/10.1161/01.atv.17.1.95; Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998;338(23):1650–1656. doi: https://doi.org/10.1056/NEJM199806043382302; Ежов М.В., Бажан С.С., Ершова А. И. и др. Клинические рекомендации по семейной гиперхолестеринемии // Атеросклероз. — 2019. — Т. 15. — № 1. — С. 58–98.; Di Taranto MD, Fortunato G. Genetic heterogeneity of Familial hypercholesterolemia: repercussions for molecular diagnosis. Int J Mol Sci. 2023;24(4):3224. doi: https://doi.org/10.3390/ijms24043224; Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide prevalence of Familial hypercholesterolemia: meta-analyses of 11 million subjects. J Am Coll Cardiol. 2020;75(20):2553–2566. doi: https://doi.org/10.1016/j.jacc.2020.03.057; Toft-Nielsen F, Emanuelsson F, Benn M. Familial hypercholesterolemia prevalence among ethnicities-systematic review and meta-analysis. Front Genet. 2022;13:840797. doi: https://doi.org/10.3389/fgene.2022.840797; Mainieri F, Tagi VM, Chiarelli F. Recent advances on Familial Hypercholesterolemia in children and adolescents. Biomedicines. 2022;10(5):1043. doi: https://doi.org/10.3390/biomedicines10051043; Wiegman A, Gidding SS, Watts GF, et al. Familial hyperc holesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36): 2425–2437. doi: https://doi.org/10.1093/eurheartj/ehv157; Чубыкина У.В., Ежов М.В., Рожкова Т.А. и др. Пятилетний период наблюдения за пациентами с гомо- и гетерозиготной семейной гиперхолестеринемией в регистре РЕНЕССАНС // Атеросклероз и дислипидемии. — 2023. — № 1. — С. 5–18. — doi: https://doi.org/10.34687/2219-8202.JAD.2023.01.0001; Леонтьева И.В. Семейная гомозиготная гиперхолестеринемия у детей: стратегия ранней диагностики и лечения // Российский вестник перинатологии и педиатрии. — 2021. — Т. 66. — № 4. — С. 118–128. — doi: https://doi.org/10.21508/10274065-2021-66-4-118-128; Леонтьева И.В. Современная стратегия диагностики и лечения семейной гетерозиготной гиперхолестеринемии у детей // Российский вестник перинатологии и педиатрии. — 2020. — Т. 65. — № 4. — С. 27–40. — doi: https://doi.org/10.21508/1027-40652020-65-4-27-40; Исаева А.С., Исакова Е.А. Генетические причины нарушений липидного обмена // Norwegian Journal of Development of the International Science. — 2018. — № 17-2. — С. 34–39.; Berberich AJ, Hegele RA. A modern approach to dyslipidemia. Endocr Rev. 2022;43(4):611–653. doi: https://doi.org/10.1210/endrev/bnab037; Futema M, Taylor-Beadling A, Williams M, Humphries SE. Genetic testing for familial hypercholesterolemia-past, present, and future. J Lipid Res. 2021;62:100139. doi: https://doi.org/10.1016/j.jlr.2021.100139; Chora JR, Iacocca MA, Tichý L, et al. The clinical genome resource (clingen) familial hypercholesterolemia variant curation expert panel consensus guidelines for LDLR variant classification. Genet Med. 2022;24(2):293–306. doi: https://doi.org/10.1016/j.gim.2021.09.012; Futema M, Ramaswami U, Tichy L, et al. Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis. 2021;319:108–117. doi: https://doi.org/10.1016/j.atherosclerosis.2021.01.008; Abou Khalil Y, Marmontel O, Ferrières J, et al. APOE molecular spectrum in a French cohort with primary dyslipidemia. Int J Mol Sci. 2022;23(10):5792. doi: https://doi.org/10.3390/ijms23105792; Cao YX, Sun D, Liu HH, et al. Improvement of definite diagnosis of familial hypercholesterolemia using an expanding genetic analysis. JACC Asia. 2021;1(1):82–89. doi: https://doi.org/10.1016/j.jacasi.2021.04.001; Loaiza N, Hartgers ML, Reeskamp LF, et al. Taking one step back in familial hypercholesterolemia: STAP1 does not alter plasma LDL (Low-Density Lipoprotein) cholesterol in mice and humans. Arterioscler Thromb Vasc Biol. 2020;40(4):973–985. doi: https://doi.org/10.1161/ATVBAHA.119.313470; Tada H, Kawashiri MA, Nomura A, et al. Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease. J Clin Lipidol. 2018;(6):1436–1444. doi: https://doi.org/10.1016/j.jacl.2018.08.006; Nishikawa R, Furuhashi M, Hori M, et al. A resuscitated case of acute myocardial infarction with both familial hypercholesterolemia phenotype caused by possibly oligogenic variants of the PCSK9 and ABCG5 genes and type I CD36 deficiency. J Atheroscler Thromb. 2022; 29(4):551–557. doi: https://doi.org/10.5551/jat.58909; Paquette M, Fantino M, Bernard S, Baass A. Paternal inheritance predicts earlier cardiovascular event onset in patients with familial hypercholesterolemia. Atherosclerosis. 2021;329:9–13. doi: https://doi.org/10.1016/j.atherosclerosis.2021.06.006; Mourre F, Giorgi R, Gallo A, et al. Maternal inheritance of familial hypercholesterolemia gene mutation predisposes to coronary atherosclerosis as assessed by calcium score in adulthood. Arterioscler Thromb Vasc Biol. 2023;43(2):94–103. doi: https://doi.org/10.1161/ATVBAHA.122.318119; Abdul-Razak S, Rahmat R, Mohd Kasim A, et al. Diagnostic performance of various familial hypercholesterolaemia diagnostic criteria compared to Dutch lipid clinic criteria in an Asian population. BMC Cardiovasc Disord. 2017;17(1):264. doi: https://doi.org/10.1186/s12872-017-0694-z; Al-Rasadi K, Al-Waili K, Al-Sabti HA, et al. Criteria for Diagnosis of Familial Hypercholesterolemia: A Comprehensive Analysis of the Different Guidelines, Appraising their Suitability in the Omani Arab Population. Oman Med J. 2014;29(2):85–91. doi: https://doi.org/10.5001/omj.2014.22; Ежов М.В., Сергиенко И.В., Рожкова Т.А. и др. Российские рекомендации по диагностике и лечению семейной гиперхолестеринемии // Атеросклероз и дислипидемии. — 2016. — № 4. — С. 21–29.; Садыкова Д.И., Галимова Л.Ф., Леонтьева И.В., Сластникова Е.С. Оценка толщины комплекса интима-медиа у детей с семейной гиперхолестеринемией // Российский вестник перинатологии и педиатрии. — 2018. — Т. 63. — № 5. — С. 152–154. — doi: https://doi.org/10.21508/1027-4065-2018-63-5-152-154; Kusters DM, Wiegman A, Kastelein JJ, Hutten BA. Carotid intimamedia thickness in children with familial hypercholesterolemia. Circ Res. 2014;114(2):307–310. doi: https://doi.org/10.1161/CIRCRESAHA.114.301430; Pan J, Liu J, Wang H, et al. Association of carotid atherosclerosis with lipid components in asymptomatic low-income Chinese: a population-based cross-sectional study. Front Neurol. 2020;11: 276. doi: https://doi.org/10.3389/fneur.2020.00276; Gidding SS, Wiegman A, Groselj U, et al. Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations. Eur J Prev Cardiol. 2022;29(18): 2301–2311. doi: https://doi.org/10.1093/eurjpc/zwac200; Schefelker JM, Peterson AL. Screening and management of dyslipidemia in children and adolescents. J Clin Med. 2022; 11(21):6479. doi: https://doi.org/10.3390/jcm11216479; Šuštar U, Mlinarič M, Kovač J, et al. Universal screening is an effective strategy for detecting patients with Familial Hypercholesterolemia. Atherosclerosis. 2022;355:7. doi: https://doi.org/10.1016/j.atherosclerosis.2022.06.021; Alonso R, Perez de Isla L, Muñiz-Grijalvo O, Mata P. Barriers to early diagnosis and treatment of familial hypercholesterolemia: current perspectives on improving patient care. Vasc Health Risk Manag. 2020;16:11–25. doi: https://doi.org/10.2147/VHRM.S192401; Галимова Л.Ф., Садыкова Д.И., Сластникова Е.С., Усова Н.Э. Диагностика семейной гиперхолестеринемии у детей: каскадный скрининг от теории к практике // Кардиоваскулярная терапия и профилактика. — 2020. — Т. 19. — № 3. — С. 191–196. — doi: https://doi.org/10.15829/1728-8800-2020-2348; Groselj U, Kovac J, Sustar U, et al. Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review. Atherosclerosis. 2018;277:383–391. doi: https://doi.org/10.1016/j.atherosclerosis.2018.06.858; Medeiros AM, Bourbon M. Genetic testing in familial hypercholesterolemia: is it for everyone? Curr Atheroscler Rep. 2023;25(4): 127–132. doi: https://doi.org/10.1007/s11883-023-01091-5; Sanin V, Schmieder R, Ates S, et al. Population-based screening in children for early diagnosis and treatment of familial hypercholesterolemia: design of the VRONI study. Eur J Public Health. 2022; 32(3):422–428. doi: https://doi.org/10.1093/eurpub/ckac007; Lazaro P, Perez de Isla L, Watts GF, et al. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia. J Clin Lipidol. 2017;11(1):260–271. doi: https://doi.org/10.1016/j.jacl.2017.01.002; Louter L, Defesche J, Roeters van Lennep J. Cascade screening for familial hypercholesterolemia: Practical consequences. Atheroscler Suppl. 2017;30:77–85. doi: https://doi.org/10.1016/j.atherosclerosissup.2017.05.019; Vanhoye X, Bardel C, Rimbert A, et al. A new 165-SNP lowdensity lipoprotein cholesterol polygenic risk score based on next generation sequencing outperforms previously published scores in routine diagnostics of familial hypercholesterolemia. Transl Res. 2022;22:1931. doi: https://doi.org/10.1016/j.trsl.2022.12.002; Lima IR, Tada MT, Oliveira TGM, et al. Polygenic risk score for hypercholesterolemia in a Brazilian familial hypercholesterolemia cohort. Atheroscler Plus. 2022;49:47–55. doi: https://doi.org/10.1016/j.athplu.2022.06.002; Tandirerung FJ. The clinical importance of differentiating monogenic familial hypercholesterolemia from polygenic hypercholesterolemia. Curr Cardiol Rep. 2022;24(11):1669–1677. doi: https://doi.org/10.1007/s11886-022-01783-5; Martin AC, Gidding SS, Wiegman A, et al. Knowns and unknowns in the care of pediatric familial hypercholesterolemia. J Lipid Res. 2017;58(9):1765–1776. doi: https://doi.org/10.1194/jlr.S074039; Lampropoulou M, Chaini M, Rigopoulos R, et al. Association between serum lipid levels in Greek children with dyslipidemia and Mediterranean diet adherence, dietary habits, lifestyle and family socioeconomic factors. Nutrients. 2020;12(6):1–15. doi: https://doi.org/10.3390/nu12061600; Hui L, Kwok ME, Nelson AE, et al. Breastfeeding in infancy and lipid profile in adolescence. Pediatrics. 2019;143(5):1–8. doi: https://doi.org/10.1542/peds.2018-3075; Williams LA, Wilson DP. Nutritional management of pediatric dyslipidemia. In: Endotext [Internet]. South Dartmouth (MA): MDText. com, Inc.; 2000. Available online: https://www.ncbi.nlm.nih.gov/books/NBK395582. Accessed on November 01, 2022.; De Jesus JM. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(Suppl 5):S213–S256. doi: https://doi.org/10.1542/peds.2009-2107C; Fiorentino R, Chiarelli F. Treatment of dyslipidaemia in children. Biomedicines. 2021;9(9):1078. doi: https://doi.org/10.3390/biomedicines9091078; Yu-Poth S, Zhao G, Etherton T, et al. Effects of the National Cholesterol Education Program’s Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. Am J Clin Nutr. 1999;69(4):632–646. doi: https://doi.org/10.1093/ajcn/69.4.632; Simell O, Niinikoski H, Rönnemaa T, et al. Cohort Profile: the STRIP Study (Special Turku Coronary Risk Factor Intervention Project), an Infancy-onset Dietary and Life-style Intervention Trial. Int J Epidemiol. 2009;38(3):650–655. doi: https://doi.org/10.1093/ije/dyn072; Manousaki D, Barnett TA, Mathieu ME, et al. Tune out and turn in: the influence of television viewing and sleep on lipid profiles in children. Int J Obes (Lond). 2020;44(5):1173–1184. doi: https://doi.org/10.1038/s41366-020-0527-5; Langslet G, Johansen AK, Bogsrud MP, et al. Thirty percent of children and young adults with familial hypercholesterolemia treated with statins have adherence issues. Am J Prev Cardiol. 2021;6: 100180. doi: https://doi.org/10.1016/j.ajpc.2021.100180; Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2019;11:CD006401. doi: https://doi.org/10.1002/14651858.CD006401.pub5; Tada H, Takamura M, Kawashiri M. Familial Hypercholesterolemia: a narrative review on diagnosis and management strategies for children and adolescents. Vasc Health Risk Manag. 2021;17: 59–67. doi: https://doi.org/10.2147/VHRM.S266249; Anagnostis P, Vaitsi K, Kleitsioti P, et al. Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trials. Endocrine. 2020;69(2):249–261. doi: https://doi.org/10.1007/s12020-020-02302-8; Braamskamp M, Langslet G, McCrindle BW, et al. Effect of rosuvastatin on carotid intima-media thickness in children with heterozygous familial hypercholesterolemia: The CHARON study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label). Circulation. 2017;136(4):359–366. doi: https://doi.org/10.1161/CIRCULATIONAHA.116.025158; Mytilinaiou M, Kyrou I, Khan M, et al. Familial Hypercholesterolemia: new horizons for diagnosis and effective management. Front Pharmacol. 2018;9:1–29. doi: https://doi.org/10.3389/fphar.2018.00707; Alonso R, Muñiz-Grijalvo O, Díaz-Díaz JL, et al. Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience. J Clin Lipidol. 2021;15(4):584–592. doi: https://doi.org/10.1016/j.jacl.2021.04.011; Santos RD, Ruzza A, Hovingh GK, et al. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020;383(14):1317–1327. doi: https://doi.org/10.1056/NEJMoa2019910; Ito MK, Sanros RD. PCSK9 Inhibition with monoclonal antibodies: modern management of hypercholesterolemia. J Clin Pharmacol. 2017;57(1):7–32. doi: https://doi.org/10.1002/jcph.766; Lee CJ, Yoon M, Kang HJ, et al. 2022 Consensus statement on the management of familial hypercholesterolemia in Korea. Korean J Intern Med. 2022;37(5):931–944. doi: https://doi.org/10.3904/kjim.2022.121; Erasmo L, Cefalu AB, Noto D, et al. Efficacy of lomitapide in the treatment of Familial Homozygous hypercholesterolemia: Results of a Real-World Clinical Experience in Italy. Adv Ther. 2017;34(5):1200–1210. doi: https://doi.org/10.1007/s12325017-0531-x; Ben-Omran T, Masana L, Kolovou G, et al. Real-World outcomes with lomitapide use in pediatric patients with homozygous familial hypercholesterolaemia. Adv Ther. 2019;36(7):1786–1811. doi: https://doi.org/10.1007/s12325-019-00985-8; Visser ME, Akdim F, Tribble DL, et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res. 2010;51(5):1057–1062. doi: https://doi.org/10.1194/jlr.M002915; Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711–720. doi: https://doi.org/10.1056/NEJMoa2004215; Hermel M, Lieberman M, Slipczuk L, et al. Monoclonal antibodies, gene silencing and gene editing (CRISPR) therapies for the treatment of hyperlipidemia-the future is here. Pharmaceutics. 2023;15(2):459. doi: https://doi.org/10.3390/pharmaceutics15020459; Roch VZ, Santos R. Past, Present, and future of Familial Hypercholesterolemia management. Methodist Debakey Cardiovasc J. 2021;17(4):28–35. doi: https://doi.org/10.14797/mdcvj.887; Tomlinson B, Patil NG, Fok M, et al. Role of PCSK9 Inhibitors in patients with Familial Hypercholesterolemia. Endocrinol Metab (Seoul). 2021;36(2):279–295. doi: https://doi.org/10.3803/EnM.2021.964; Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020:16;382(16):1520–1530. doi: https://doi.org/10.1056/NEJMoa1913805; Reijman MD, Schweizer A, Peterson ALH, et al. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia. Eur J Prev Cardiol. 2022;29(9):1361–1368. doi: https://doi.org/10.1093/eurjpc/zwac025; Ishigaki Y, Kawagishi N, Hasegawa Y, et al. Liver transplantation for homozygous familial hypercholesterolemia. J Atheroscler Thromb. 2019;26(2):121–127. doi: https://doi.org/10.5551/jat.RV17029; Björkegren JLM, Lusis AJ. Atherosclerosis: Recent developments. Cell. 2022;185(10):1630–1645. doi: https://doi.org/10.1016/j.cell.2022.04.004; Berta E, Zsiros N, Bodor M, et al. Clinical aspects of genetic and non-genetic cardiovascular risk factors in familial hypercholesterolemia. Genes. 2022;13(7):1–19. doi: https://doi.org/10.3390/genes13071158; Braamskamp MJ, Kusters DM, Avis HJ, et al. Patients with familial hypercholesterolemia who initiated statin treatment in childhood are at lower risk for CHD then their affected parents. Circulation. 2013;128(Suppl 22):A17837.; Kesavan G. Innovations in CRISPR-Based Therapies. Mol Biotechnol. 2023;65(2):138–145. doi: https://doi.org/10.1007/s12033-021-00411-x; Asmamaw M, Zawdie B. Mechanism and applications of CRISPR/ Cas-9-Mediated Genome Editing. Biologics. 2021;15:353–361. doi: https://doi.org/10.2147/BTT.S326422; Alnouri F, Santos RD. New trends and therapies for familial hypercholesterolemia. J Clin Med. 2022;11(22):6638. doi: https://doi.org/10.3390/jcm11226638; Zhao H, Li Y, He L, et al. In Vivo AAV-CRISPR/Cas9-mediated gene editing ameliorates atherosclerosis in familial hypercholesterolemia. Circulation. 2020;141(1):67–79. doi: https://doi.org/10.1161/CIRCULATIONAHA.119.042476; Močnik M, Marčun Varda N. Lipid biomarkers and atherosclerosisold and new in cardiovascular risk in childhood. Int J Mol Sci. 2023; 24(3):2237. doi: https://doi.org/10.3390/ijms24032237; Fricaudet M, Di-Filippo, Mouli P, et al. Performance assessment of salivary screening in familial hypercholesterolemia in children. Atherosclerosis. 2021;331:E183. doi: https://doi.org/10.1016/j.atherosclerosis.2021.06.558
-
11Academic Journal
Source: Сучасна педіатрія. Україна; № 8(128) (2022): Сучасна педіатрія. Україна; 12-20
Modern Pediatrics. Ukraine; No. 8(128) (2022): Modern pediatrics. Ukraine; 12-20
Modern Pediatrics. Ukraine; № 8(128) (2022): Modern pediatrics. Ukraine; 12-20Subject Terms: комплекс інтима-медіа, familial hypercholesterolemia, ліпідний профіль, lipoprotein (a), аполипопротеин B, аполипопротеин A1, діти, аполіпопротеїн B, dp-uc matrix Gla protein, дети, intima-media complex thickness, матриксный Gla белок, липопротеин (а), 3. Good health, матриксний Gla-білок, lipid profile, семейная гиперхолестеринемия, children, комплекс интима-медиа, сімейна гіперхолестеринемія, apolipoprotein A1, ліпопротеїн (а), apolipoprotein B, липидный профиль, аполіпопротеїн A1
File Description: application/pdf
Access URL: http://mpu.med-expert.com.ua/article/view/273144
-
12Academic Journal
Authors: A. Blokhina V., A. Ershova I., A. Limonova S., O. Kopylova V., A. Meshkov N., O. Drapkina M., А. Блохина В., А. Ершова И., А. Лимонова С., О. Копылова В., А. Мешков Н., О. Драпкина М.
Contributors: The study was performed with the support of the National Medical Research Center for Therapy and Preventive Medicine., Исследование проведено при поддержке Национального медицинского исследовательского центра терапии и профилактической медицины.
Source: Rational Pharmacotherapy in Cardiology; Vol 17, No 6 (2021); 808-815 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 6 (2021); 808-815 ; 2225-3653 ; 1819-6446
Subject Terms: PCSK9 inhibitors, familial hypercholesterolaemia, hyperlipidemia, lipid clinics, outpatient practice, preventive medicine, ингибиторы PCSK9, семейная гиперхолестеринемия, гиперлипидемия, липидная клиника, амбулаторная практика, профилактическая медицина
File Description: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/2626/2261; Townsend N, Wilson L, Bhatnagar P, et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2016;37(42):3232-45. DOI:10.1093/EURHEARTJ/EHW334.; Ference B, Ginsberg H, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-72. DOI:10.1093/EURHEARTJ/EHX144.; Mach F, Baigent C, Catapano ALб et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-88. DOI:10.1093/EURHEARTJ/EHZ455.; Кухарчук В.В., Ежов М.В., Сергиенко И.В., и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020;1(38):7-40. DOI:10.34687/2219-8202.JAD.2020.01.0002.; Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004;173(1):55-68. DOI:10.1016/j.atherosclerosis.2003.11.010.; Zafrir B, Jubran A. Lipid‐lowering therapy with PCSK 9‐inhibitors in the real‐world setting: Two‐year experience of a regional lipid clinic. Cardiovascular Therapeutics. 2018;36(5):e12439. DOI:10.1111/1755-5922.12439.; Rane PB, Patel J, Harrison DJ, et al. Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors. Am J Cardiovasc Drugs. 2018;18(2):103-8. DOI:10.1007/s40256-017-0246-z.; Jensen JS, Weeke PE, Bang LE, et al. Clinical characteristics and lipid lowering treatment of patients initiated on proprotein convertase subtilisin-kexin type 9 inhibitors: a nationwide cohort study. BMJ Open. 2019;9(4):e022702. DOI:10.1136/bmjopen-2018-022702.; Turgeon RD, Tsuyuki RT, Gyenes GT, Pearson GJ. Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY OUTCOMES Trial. Can J Cardiol. 2018;34(12):1600-5. DOI:10.1016/j.cjca.2018.04.002.; Matta A, Bongard V, Bouisset F, et al. Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2021;27:e928784-1. DOI:10.12659/MSM.928784.; Stoekenbroek RM, Hartgers ML, Rutte R, et al. PCSK9 inhibitors in clinical practice: Delivering on the promise? Atherosclerosis. 2018;270:205-10. DOI:10.1016/j.atherosclerosis.2017.11.027.; Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects. J Am Coll Cardiol. 2020;75(20):2553-66. DOI:10.1016/j.jacc.2020.03.057.; Meshkov AN, Ershova AI, Kiseleva AV, et al. The Prevalence of Heterozygous Familial Hypercholesterolemia in Selected Regions of the Russian Federation: The FH-ESSE-RF Study. J Pers Med. 2021;11(6):464. DOI:10.3390/jpm11060464.; Ежов М.В., Бажан С.С., Ершова А.И., и др. Клинические рекомендации по семейной гиперхолестеринемии. Атеросклероз. 2019;15(1):58-98.; Piccinni C, Antonazzo IC, Maggioni AP, et al. PCSK9 Inhibitors' New Users: Analysis of Prescription Patterns and Patients' Characteristics from an Italian Real-world Study. Clin Drug Investig. 2020;40(2):173-81. DOI:10.1007/s40261-019-00877-3.; Schmidt AF, Pearce LS, Wilkins JT, et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2017;4(4):CD011748. DOI:10.1002/14651858.CD011748.pub2.; Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-22. DOI:10.1056/NEJMoa1615664.; Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097-107. DOI:10.1056/NEJMoa1801174.; Блохина А.В., Ершова А.И., Мешков А.Н., и др. Липидная клиника как эффективная модель профилактической медицины. Рациональная Фармакотерапия в Кардиологии. 2021;17(1):4-10. DOI:10.20996/1819-6446-2021-01-02.; Pechlivanis S, Mahabadi AA, Hoffmann P, et al. Association between lipoprotein (a)(Lp (a)) levels and Lp (a) genetic variants with coronary artery calcification. BMC Med Genet. 2020;21(1):1-10. DOI:10.1186/s12881-020-01003-3.; Gaudet D, Watts GF, Robinson JG, et al. Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program). Am J Cardiol. 2017;1;119(1):40-6. DOI:10.1016/j.amjcard. 2016.09.010.; Raal FJ, Giugliano RP, Sabatine MS, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol. 2014;8;63(13):1278-88. DOI:10.1016/j.jacc.2014.01.006.; https://www.rpcardio.com/jour/article/view/2626
-
13Academic Journal
Authors: Olesya E. Astafurova, Vasiliy V. Kashtalap, Olga Gruzdeva, Natalia V. Fedorova, Dmitriy L. Shukevich, Roman A. Kornelyuk, Olga Barbarash
Source: Фундаментальная и клиническая медицина, Vol 3, Iss 4, Pp 113-125 (2018)
-
14Academic Journal
Authors: M. Ezhov V., V. Kukharchuk V., I. Sergienko V., N. Akhmedzhanov M., M. Voevoda I., V. Gurevich S., V. Kashtalap V., V. Konstantinov O., V. Skibitsky V., I. Shaposhnik I., M. Ежов В., В. Кухарчук В., И. Сергиенко В., Н. Ахмеджанов М., М. Воевода И., В. Гуревич С., В. Кашталап В., В. Константинов О., В. Скибицкий В., И. Шапошник И.
Source: Rational Pharmacotherapy in Cardiology; Vol 17, No 1 (2021); 169-172 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 1 (2021); 169-172 ; 2225-3653 ; 1819-6446
Subject Terms: familial hypercholesterolemia, mixed dyslipidemia, hypolipidemic therapy, семейная гиперхолестеринемия, смешанная дислипидемия, гиполипидемическая терапия
File Description: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/2403/2129; Здравоохранение в России 2019. Статистический сборник. М.: Росстат; 2019.; Heart and Circulatory Disease Statistics 2019. Published by the BHF in collaboration with the Institute of Applied Health Research at the University of Birmingham [cited by Jan 10, 2021]. Available from: www.bhf.org.uk/statistics.; State of Health in the EU. Germany. Country Health Profile 2019 [cited by Jan 10, 2021]. Available from: http://www.oecd.org/publications/germany-country-health-profile-2019-36e21650-en.htm.; Бойцов С.А., Шальнова С.А., Деев А.Д. Смертность от сердечно-сосудистых заболеваний в Российской Федерации и возможные механизмы ее изменения. Журнал Неврологии и Психиатрии им. С.С. Корсакова. 2018;118(8):98-10. DOI:10.17116/jnevro201811808198.; Бойцов С.А., Демкина А.Е., Ощепкова Е.В., и др. Достижения и проблемы практической кардиологии на современном этапе. Кардиология. 2019;59(3):53-9. DOI:10.18087/cardio.2019.3.10242.; Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Prev Med. 1986;15(3):254-73. DOI:10.1016/0091-7435(86)90045-9.; Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский Кардиологический Журнал 2018;23(6):7-122. DOI:10.15829/1560-4071-2018-6-7-122.; 2019 ESC/EAS Guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205. DOI:10.1016/j.atherosclerosis.2019.08.014.; Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и Дислипидемии. 2020;1:7-34.; 2018/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol; A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285-e350. DOI:10.1016/j.jacc.2018.11.003.; Методические рекомендации по организации медицинской помощи больным с наследственными атерогенными нарушениями липидного обмена в субъектах РФ. Атеросклероз и Дислипидемии. 2016;4:15-20.; Ежов М.В., Близнюк С.А., Тмоян Н.А., и др. Регистр пациентов с семейной гиперхолестеринемией и пациентов очень высокого сердечно-сосудистого риска с недостаточной эффективностью, проводимой гиполипидемической терапии (РЕНЕССАНС). Российский Кардиологический Журнал. 2019;24(5):7-13. DOI:10.15829/1560-4071-2019-5-7-13.; https://www.rpcardio.com/jour/article/view/2403
-
15Academic Journal
Authors: OLGA L. Barbarash, NATALIA V. Fedorova, VASILIY V. Kashtalap, ROMAN A. Kornelyuk, OLESYA E. Astafurova, DMITRIY L. Shukevich, OLGA V. Gruzdeva
Source: Фундаментальная и клиническая медицина, Vol 3, Iss 4, Pp 113-125 (2018)
Subject Terms: дислипидемия, семейная гиперхолестеринемия, help-аферез, dyslipidemia, familial hypercholesterolemia, help-apheresis, Medicine (General), R5-920
File Description: electronic resource
-
16Academic Journal
Authors: Yakimenko, O. O., Maznichenko, Ie. O.
Source: Bulletin of Scientific Research; No. 3 (2018); 146-151 ; Вестник научных исследований; № 3 (2018); 146-151 ; Вісник наукових досліджень; № 3 (2018); 146-151 ; 2415-8798 ; 1681-276X ; 10.11603/2415-8798.2018.3
Subject Terms: familial hypercholesterolemia, hypolipidemic therapy, statins, семейная гиперхолестеринемия, гиполипидемическая терапия, статины, сімейная гіперхолестеринемія, гіполіпідемічна терапія, статини
File Description: application/pdf
Relation: https://ojs.tdmu.edu.ua/index.php/visnyk-nauk-dos/article/view/9412/9222; https://repository.tdmu.edu.ua//handle/123456789/12730
-
17Academic Journal
Authors: D. I. Sadykova, M. A. Shkolnikova, L. F. Galimova, E. S. Slastnikova, Д. И. Садыкова, М. А. Школьникова, Л. Ф. Галимова, Е. С. Сластникова
Source: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 65, № 5 (2020); 139-144 ; Российский вестник перинатологии и педиатрии; Том 65, № 5 (2020); 139-144 ; 2500-2228 ; 1027-4065 ; 10.21508/1027-4065-2020-65-5
Subject Terms: побочное действие, familial hypercholesterolemia, total cholesterol, low density lipoproteins, treatment, statins, efficacy, side effects, семейная гиперхолестеринемия, общий холестерин, липопротеины низкой плотности, лечение, ста-тины, эффективность
File Description: application/pdf
Relation: https://www.ped-perinatology.ru/jour/article/view/1249/994; Mathers C.D., Iburg B.K., Fat M.D., Shibuya K., Inoue M., Stein C. et al. Global Burden of Disease in 2002: data sources, methods and results. Global Programme on Evidence for Health Policy Discussion Paper No. 54 World Health Organization December 2003. https://www.who.int/healthinfo/pa-per54.pdf.; Weiss L.A., Pan L., Abney M., Ober C. The sex-specific genetic architecture of quantitative traits in humans. Nature Genetics 2006; 38(2): 218-222. DOI:10.1038/ng1726; Arnett D.K., Blumenthal R.S., Albert M.A., Buroker A.B., Gold-berger Z.D., Hahn E.J. et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 140(11): e596—e646. DOI:10.1161/CIR.0000000000000678; Ежов М.В., Близнюк С.А., Тмоян Н.А. Рожкова Т.А., Ду-пляков Д.В., Сальченко В.А. и др. Регистр пациентов с семейной гиперхолестеринемией и пациентов оченьвысокого сердечно-сосудистого риска с недостаточной эффективностью проводимой гиполипидемической терапии (РЕНЕССАНС). Российский кардиологический журнал 2019; 5: 7—13. DOI:10.15829/1560-4071-2019-5-7-13; Классификация и эффекты статинов. [Электронный ресурс]. https://noatero.ru/ru/klassifikaciya-i-effekty-statinov; Ference B.A., Ginsberg H.N., Graham I., Ray K.K., Packard C.J., Bruckerd E. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38: 2459-2472. DOI:10.1093/eurheartj/ehx144; Grundy S.M., Arai H, Barter P., Bersot T.P., Betteridge D.J., Carmena R. et al. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia — full report. J Clin Lipidol 2014; 8: 29-60. DOI:10.1016/j.jacl.2013.12.005; Luirink I.K., Wiegman A., Kusters D.M., Hof M.H., Groothoff J.W., de Groot E. et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. New Engl J Med 2019; 381(16): 1547—1556. DOI:10.1056/nejmoa1816454; Wiegman A., Gidding S.S., Watts G.F., Chapman M.J., Ginsberg H.N., Cuchel M. et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 36(36): 2425—2437. DOI:10.1093/eurheartj/ehv157; Clauss S.B., Holmes K.W., Hopkins P., Stein E., Cho M., Tate A.C. et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics 2005; 116: 682—688. DOI:10.1542/peds.2004-2090; Wiegman A., Hutten B.A., de Groot E., Rodenburg J., Bac-cer H., Buller H. R. et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2014; 292: 331—337. DOI:10.1001/jama.292.3.331; Mamann N., Lemale J., Karsenty A., Dubern B., Girardet J.-P., Tounian P. Intermediate-Term Efficacy and Tolerance of Statins in Children. J Pediatr 2019; 210: 161—165. DOI:10.1016/j.jpeds.2019.03.032; McCrindle B.W., Ose L., Marais A.D. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr 2013; 142: 74—80. DOI:10.1016/j.accreview.2003.09.056; Vuorio A., Kuoppala J., Kovanen P.T., Humphries S.E., Tons-tad S., Wiegman A. et al. Statins for children with familial hypercholesterolemia. Cochrane Database of Syst Rev 2019; 11: CD006401. DOI:10.1002/14651858.cd006401.pub5; Avis H.J., Hutten B.A., Gagne C., Langslet G., McCrindle B.W., Wiegman A. et al. Efficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia. J Am Coll Cardiol 2010; 55(11): 1121—1126. DOI:10.1016/j.jacc.2009.10.042; Raitakari O.T., Juonala M., Kahonen M., Taittonen L., Lai-tinen T., Maki-Torkko N. et al. Cardiovascular risk factors in children and carotid intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 2003; 290: 2277—2283. DOI:10.1001/jama.290.17.2277; Kusters D.M., Wiegman A., Kastelein J.J.P., Hutten B.A. Carotid Intima-Media Thickness in Children With Familial Hypercholesterolemia. Circulation Res 2013; 114(2): 307— 310. DOI:10.1161/circresaha.114.301430; Braamskamp M.J., Hutten B.A., Wiegman A. Early initiation of statin treatment in children with familial hypercholes-terolaemia. Curr Opin Lipidol 2015; 26(3): 236—239. DOI:10.1097/mol.0000000000000177; De Jongh S., Lilien M.R., op’t Roodt J., Stroes E.S., Bak-ker H.D., Kastelein J.J. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002; 40(12): 2117—2121. DOI:10.1016/s0735-1097(02)02593-7; Harada-Shiba M., Ohta T., Ohtake A., Ogura M., Dobashi K., Nohara A. et al. Guidance for Pediatric Familial Hypercholesterolemia 2017. J Atheroscler Thromb 2018; 25(6): 539—553. DOI:10.5551/jat.14621; Watts G., Gidding S., Wierzbicki A., Toth P. P., Alonso R., Brown W.V. et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Inter J Cardiol 2014; 171: 309—325. DOI: 1016/j.ijcard.2013.11.025; Goldberg A.C., Hopkins P.N., Toth P.P., Ballantyne C.M., Rader D.J., Robinson J.G. et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5(3 Suppl): S1—8. DOI:10.1016/j.jacl.2011.03.001; Descamps O.S., Tenoutasse S., Stephenne X., Gies I., Beau-loye V., Lebrethon M.C. et al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis 2011; 218(2): 272—280. DOI:10.1016/j.atherosclerosis.2011.06.016; Kennedy M.J., Jellerson K.D., Snow M.Z., Zacchetti M.L. Challenges in the pharmacologic management of obesity and secondary dyslipidemia in childrenand adolescents. Pediatr Drugs 2013; 15: 335—342. DOI:10.1007/s40272-013-0028-2; De Ferranti S., Ludwig D.S. Storm over statins—the controversy surrounding pharmacologic treatment of children. N Engl J Med 2008; 359(13): 1309—1312. DOI:10.1056/NEJMp0805953; Wagner J.B. Children Are Not Small Adults: Specific Findings in Statin Exposure and Response in a Growing Population. Clin Pharmacol Therap 2019; 106(2): 278—280. DOI:10.1002/cpt.1431; Thompson P.D. Statin-Associated Myopathy. JAMA 2003; 289: 1681. DOI:10.1001/jama.289.13.1681; Avis H.J., Vissers M.N., Stein E.A. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2007; 27: 1803—1810. DOI:10.1161/ATVBAHA.107.145151; Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casu-la M., Badimon L. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111—188. DOI:10.1093/eu-rheartj/ehz455; Desai N.K., Mendelson M.M., Baker A., Ryan H.H., Griggs S., Boghani M. et al. Hepatotoxicity of Statins as Determined by Serum Alanine Aminotransferase in a Pediatric Cohort With Dyslipidemia. JPGN 2019; 68; 2: 175—181. DOI:10.1097/MPG.0000000000002174; Vuorio A., Kuoppala J., Kovanen P.T., Humphries S. E., Tonstad S., Wiegman A. et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev 2019; 2019(11): CD006401. DOI:10.1002/14651858.CD006401.pub5; Wiegman A., Gidding S.S., Watts G.F., Chapman M.J., Ginsberg H.N., Cuchel M. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 36(36): 2425— 2437. DOI:10.1093/eurheartj/ehv157; Shafiq N., Bhasin B., Pattanaik S., Pandhi P, Venkate-shan S.P., Singh M. et al. A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia. Int J Clin Pharmacol Therap 2007; 45: 548—555. DOI:10.5414/CPP45548; Carreau V., Girardet J.P., Bruckert E. Long-term follow-up of statin treatment in a cohort of children with familial hypercholesterolemia. Efficacy and tolerability. Pediatr Drugs.2011; 13: 267-275. DOI:10.2165/11591650-000000000-00000; Besseling J., Kastelein J.J., Defesche J.C., Hutten B.A., Ho-vingh G.K. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA 2015; 313(10): 358-361. DOI:10.1001/jama.2015.1206; Kusters D.M., Wiegman A., Kastelein J.J.P., Hutten B.A. Carotid Intima-Media Thickness in Children With Familial Hypercholesterolemia. Circulation Res 2013, 114(2): 307-310. DOI:10.1161/circresaha.114.301430; Joyce N., Zachariah J.P., Eaton C.B., Trivedi A.N., Welle-nius G.A. Statin Use and the Risk of Type 2 Diabetes Mellitus in Children and Adolescents. Acad Pediatr 2017; 17(5): 515— 522. DOI:10.1016/j.acap.2017.02.006; Grundy S.M., Stone N.J., Bailey A.L., Beam C., Birtc-her K.K., Blumenthal R.S. et al. 2018 AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139(25): e1082-e1143. DOI:10.1161/CIR.0000000000000625; Ramaswami U., Futema M., Bogsrud M.P., Holven K.B., Roeters van Lennep J., Wiegman A. et al. Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis 2020; 292: 178-187. DOI:10.1016/j.atherosclerosis.2019.11.012; Клинические рекомендации. Семейная гиперхолестеринемия. 2018 г. https://noatero.ru/sites/default/files/proekt_klinicheskie_rekomendacii_sghs_mz_rf_18.01.pdf.
-
18Academic Journal
Authors: L. F. Galimova, D. I. Sadykova, I. V. Leontyeva, E. S. Slastnikova, N. Sh. Kurmaeva, Л. Ф. Галимова, Д. И. Садыкова, И. В. Леонтьева, Е. С. Сластникова, Н. Ш. Курмаева
Source: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 65, № 5 (2020); 169-175 ; Российский вестник перинатологии и педиатрии; Том 65, № 5 (2020); 169-175 ; 2500-2228 ; 1027-4065 ; 10.21508/1027-4065-2020-65-5
Subject Terms: эндотелин-1, familial hypercholesterolemia, endothelial dysfunction, flow-dependent vasodilation, nitrogen oxide, endothelin-1, семейная гиперхолестеринемия, дисфункция эндотелия, потокзависимая вазодилатация, оксид азота
File Description: application/pdf
Relation: https://www.ped-perinatology.ru/jour/article/view/1254/999; Клинические рекомендации. Семейная гиперхолестеринемия. 2018 г. Электронный источник: https://noatero.ru/sites/default/files/proekt_klinicheskie_rekomendacii_sghs_mz_rf_18.01.pdf.; Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L. et al. ESC Scientific Document Group, 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2020; 41(1): 111—188. Doi:10.1093/eurheartj/ehz455.; Bays H.E., Jones P.H., Orringer W., Brown V., Jacobson T.A. National Lipid Association Annual Summary of Clinical Lip-idology. J Clin Lipidol 2016; 10(1): S1-S43. DOI:10.1016/j.jacl.2015.08.002; Vallejo-Vaz A.J., Kondapally Seshasai S.R., Cole D, Hovingh G.K., Kastelein J.J., Mata P. et al. Familial hypercho-lesterolaemia: a global call to arms. Atherosclerosis 2015; 243: 257-59. DOI:10.1016/j.atherosclerosis.2015.09.021; Pecin I., Hartgers M.L., Hovingh G.K., Dent R., Reiner-et Z. Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: the role of PCSK9 inhibitors. Eur J Prev Cardiol 2017; 24: 1383-1401. DOI:10.1177/2047487317717346; Urbina E.M. Abnormalities of vascular structure and function in pediatric hypertension. Pediatr Nephrol 2016; 31: 10611070. DOI:10.1007/s00467-015-3188-1; Litwin M., Niemirska A. Intima-media thickness measurements in children with cardiovascular risk factors. Pediatr Nephrol 2009; 24: 707-719. DOI:10.1007/s00467-008-0962-3; Narverud I., Retterst0l K, Iversen P.O., Halvorsen B, Ueland T., Ulven, S.M. et al. Markers of atherosclerotic development in children with familial hypercholesterolemia: A literature review. Atherosclerosis 2014; 235(2): 299-309. DOI:10.1016/j.atherosclerosis.2014.05.917; Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med Overseas Ed 1999; 340: 115-126.; Favero G., Paganelli C., Buffoli B., Rodella L.F., Rezzani R. Endothelium and Its Alterations in Cardiovascular Diseases: Life Style Intervention. Biomed Res Int 2014; 2014: 801896. DOI:10.1155/2014/801896; Vita J.A. Endothelial Function. Circulation 2011; 124(25): e906-e912. DOI:10.1161/CIRCULATIONAHA.111.078824; Сергеева Е.В., Садыкова Д.И. Эндотелин-1 как маркер эндотелиальной дисфункции при различных формах эссенциальной артериальной гипертензией у подростков. Рос вестн перинатол и педиатр 2016; 61(4): 176-177.; АхметзяновВ.Ф., Латфуллин И.А., Нигматуллина Р.Р. Современные представления о роли серотонинергической системы в регуляции сердечно-сосудистой деятельности в норме и патологии. Казанский медицинский журнал 2006; 2: 119-121.; Davies P.F., Spaan J.A., Krams R. Shear stress biology of the endothelium. Ann of Biomed Engin 2005; 33(12): 17141718. DOI:10.1007/s10439-005-8774-0; Khaddaj Mallat R., Mathew John C., Kendrick D.J., Braun A.P. The vascular endothelium: A regulator of arterial tone and interface for the immune system. Crit Rev Clin Lab Sci 2017; 54(7-8): 458-470. DOI:10.1080/10408363.2017.1394267; Дремина Н.Н., Шурыгин М.Г., Шурыгина И.А. Эндотели-ны в норме и патологии. Международный журнал прикладных и фундаментальных исследований 2016; 10: 210-214.; Iglarz M., Schiffrin E.L. Role of endothelin-1 in hypertension. Curr Hypertens Rep 2003; 5(2): 144-148. DOI:10.1007/s11906-003-0071-4; Chan E.A., Buckley B., Farraj A.K., Thompson L.C. The heart as an extravascular target of endothelin-1 in particulate matter-induced cardiac dysfunction. Pharmacol Ther 2016; 165: 63-78. DOI:10.1016/j.pharmthera.2016.05.006; Cesari M., Pavan E., Sacchetto A., Rossi G.P. Endothelin-1: a scientist’s curiosity, or a real player in ischemic heart disease? Am Heart J 1996; 132(6): 1236-1243. DOI:10.1016/s0002-8703(96)90468-8; Marin E., Sessa W.C. Role of endothelial-derived nitric oxide in hypertension and renal disease. Curr Opin Nephrol Hypertens 2007; 16(2): 105-110. DOI:10.1097/MNH.0b013e328017f893; Incalza M.A., D’Oria R., Natalicchio A., Perrini S., Lavio-la L., Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul Pharmacol 2018; 100: 1-19. DOI:10.1016/j.vph.2017.05.005; Barath A., Turi S., Nemeth I., Bereczki C., Gellen B., Haszon I. et al. Different pathomechanisms of essential and obesity-associated hypertension in adolescents. Pediatr Nephrol 2006; 21(10): 1419-1425. DOI:10.1007/s00467-006-0215-2; Neunteufl T., Heher S., Katzenschlager R., Wolfl G., Kost-ner K., Maurer G. et al. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 2000; 86(2): 207-210. DOI:10.1016/S0002-9149(00)00857-2; Suwaidi J.A., Hamasaki S., Higano S.T., Nishimura R.A., Holmes Jr.D.R., Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunc-tion. Circulation 2000; 101: 948-954. DOI:10.1161/01.cir.101.9.948; Neil H.A., Hammond T., Huxley R., Matthews D.R., Humphries S.E. Extent of underdiagnosis of familial hypercho-lesterolaemia in routine practice: prospective registry study. BMJ 2000; 321(7254): 148. DOI:10.1136/bmj.321.7254.148; Corretti M.C., Anderson T.J., Benjamin E.J., Celermajer D., Charbonneau F., Creager M.A. et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. J Am Coll Cardiol 2002; 39(2): 257-265. DOI:10.1016/s0735-1097(01)01746-6; Nishiyama H., Richardson R.S. Ultrasound Assessment of Flow-Mediated Dilation: A Tutorial. Hypertension 2010; 55(5): 1075-1085. DOI: 0.1161/HYPERTENSIONA-HA.110.150821; Tousoulis D., Kampoli A.-M., Tentolouris Nikolaos Papageor-giou C, Stefanadis C. The Role of Nitric Oxide on Endothelial Function. Curr Vasc Pharmacol 2012; 10(1): 4-18. DOI:10.2174/157016112798829760; Aflyatumova G.N., Nigmatullina R.R., Sadykova D.I., Chi-bireva M.D., Fugetto F, Serra R. Endothelin-1, nitric oxide, serotonin and high blood pressure in male adolescents. Vasc Health Risk Manag 2018; 14: 213-223. DOI:10.2147/VHRM.S170317; Klinger J.R., Abman S.H., Gladwin M.T. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension. Am J Respir Crit Care Med 2013; 188(6): 639-646. DOI:10.1164/rccm.201304-0686PP; Lo H.C., Lin S.C., Wang Y.M. The relationship among serum cytokines, chemokine, nitric oxide, and leptin in children with type 1 diabetes mellitus. Clin Biochem 2004; 37(8): 666— 672. DOI:10.1016/j.clinbiochem.2004.02.002; Hsu C.N., Lu P.C., Lo M.H., Lin I.C., Tain Y.L. The Association between Nitric Oxide Pathway, Blood Pressure Abnormalities, and Cardiovascular Risk Profile in Pediatric Chronic Kidney Disease. Int J Mol Sci 2019; 20(21): 5301. DOI:10.3390/ijms20215301; Sorensen K.E., Celermajer D.S., Georgakopoulos D., Hatcher G, Betteridge D.J., Deanfield J.E. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipopro-tein(a) level. J Clin Invest 1994; 93: 50-55.; Celermajer D.S., Sorensen K.E., Gooch V.M., Spiegelhal-ter D.J., Miller O.I., Sullivan I.D. et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111e5.; Aggoun Y., Szezepanski I., Bonnet D. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events in children. Pediatr Res 2005; 58: 173-178. DOI:10.1203/01.PDR.0000170900.35571.CB; Aggoun Y., Bonnet D., Sidi D., Girardet J.P., Bucker E., Polak M. et al. Arterial mechanical changes in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20: 2070-2075. DOI:10.1161/01.atv.20.9.2070; Vlahos A.P., Naka K.K., Bechlioulis A., Theoharis P., Vaka-lis K., Moutzouri E. et al. Endothelial Dysfunction, But Not Structural Atherosclerosis, Is Evident Early in Children With Heterozygous Familial Hypercholesterolemia. Pediatr Cardiol 2013; 35(1): 63-70. DOI:10.1007/s00246-013-0742-0; Mietus-Snyder M., Malloy M.J. Endothelial dysfunction occurs in children with two genetic hyperlipidemias: Improvement with antioxidant vitamin therapy. J Pediatrics 1998; 133(1): 35-40. DOI:10.1016/s0022-3476(98)70174-x; De Jongh S., Lilien M.R., Bakker H.D., Hutten B.A., Kaste-lein J.J.P., Stroes E.S.G. Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia. Atherosclerosis 2002; 163(1): 193197. DOI:10.1016/s0021-9150(02)00003-5; Jehlicka P., Stozicky F., Mayer Jr. O., Varvarovska J., Racek J., Trefil L. et al. Asymmetric dimethylarginine and the effect of folate substitution in children with familial hypercholesterolemia and diabetes mellitus type 1. Physiol Res 2009; 58: 179-184.; Fabbri-Arrigoni F.I., Clarke L., Wang G., Charakida M., Ellins E., Halliday N. et al. Levels of circulating endothelial cells and colony-forming units are influenced by age and dys-lipidemia. Pediatr Res 2012; 72(3): 299-304. DOI:10.1038/pr.2012.76; Каде А.Х., Занин С.А., Губарева Е.А., Туровая А.Ю., Богданова Ю.А., Апсалямова С.О., Мерзлякова С.Н. Физиологические функции сосудистого эндотелия. Фундаментальные исследования 2011; 11(3): 611-617.; Голивец Т.П., Дубоносова Д.Г., Осипова О.А., Петрова Г.Д. Эффекты эндотелина-1 в развитии и прогрессировании метаболического синдрома и других социально значимых неинфекционных заболеваний (обзор литературы). Научные ведомости БелГУ. Серия: Медицина. Фармация 2017; 19(268): 5-19.; Boren J., Chapman M.J., Krauss R.M., Packard C.J., Bent-zon J.F., Binder C. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2020; 1(24): 2313-2330. DOI:10.1093/eurheartj/ehz962; Grundy S.M., Stone N.J., Bailey A.L., Beam C., Birt-cher K.K., Blumenthal R.S. et al. 2018 AhA/ACC/AaCvPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139(25): e1082-e1143. DOI:10.1161/CIR.0000000000000625; Luirink I.K., Wiegman A., Kusters D.M., Hof M.H., Groothoff J.W., de Groot E. et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. New Engl J Med 2019; 381(16): 1547-1556. DOI:10.1056/nejmoa1816454
-
19Academic Journal
Authors: A. Meshkov N., A. Ershova I., S. Shalnova A., A. Alieva S., S. Bazhan S., O. Barbarash L., D. Bogdanov Y., I. Viktorova A., Yu. Grinshtein I., D. Duplyakov V., O. Kalachikova N., A. Kontsevaya V., R. Libis A., I. Medvedeva V., V. Nevzorova A., N. Prishchepa N., O. Rotar P., V. Serebryakova N., I. Trubacheva A., T. Chernykh M., E. Shutemova A., O. Drapkina M., S. Boytsov A., А. Мешков Н., А. Ершова И., С. Шальнова А., А. Алиева С., С. Бажан С., О. Барбараш Л., Д. Богданов Ю., И. Викторова А., Ю. Гринштейн И., Д. Дупляков В., О. Калачикова Н., А. Концевая В., Р. Либис А., И. Медведева В., В. Невзорова А., Н. Прищепа Н., О. Ротарь П., В. Серебрякова Н., И. Трубачева А., Т. Черных М., Е. Шутемова А., О. Драпкина М., С. Бойцов А.
Contributors: The study has financial support from Amgen grant No. 266909, Исследование выполнено за счет средств гранта компании Амджен №266909
Source: Rational Pharmacotherapy in Cardiology; Vol 16, No 1 (2020); 24-32 ; Рациональная Фармакотерапия в Кардиологии; Vol 16, No 1 (2020); 24-32 ; 2225-3653 ; 1819-6446
Subject Terms: ESSE-RF study, familial hypercholesterolemia, prevalence, Russian Federation, ЭССЕ-РФ исследование, семейная гиперхолестеринемия, распространенность, Российская Федерация
File Description: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/2122/1914; Мешков А.Н., Малышев П.П., Кухарчук В.В. Семейная гиперхолестеринемия в России: генетическая и фенотипическая характеристика. Терапевтический Архив. 2009;81(9):23-8.; Akioyamen L.E., Genest J., Shan S.D., et al. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open. 2017;7(9):e016461. DOI:10.1136/bmjopen-2017-016461.; Ershova A.I., Meshkov A.N., Bazhan S.S., et al. The prevalence of familial hypercholesterolemia in the West Siberian region of the Russian Federation: A substudy of the ESSE-RF. PLoSOne. 2017;12(7):e0181148. DOI:10.1371/journal.pone.0181148.; Ershova A.I., Meshkov A.N., Bazhan S.S., et al. The prevalence of heterozygous familial hypercholesterolemia in the Russian Federation: A substudy of the ESSE-Rf. Atherosclerosis. 2017;263:e184-e185; Бойцов С.А., Чазов Е.И., Шляхто Е.В., и др. Научно-организационный комитет проекта ЭССЕ-РФ. Эпидемиология сердечно-сосудистых заболеваний в различных регионах России (ЭССЕ-РФ). Обоснование и дизайн исследования. Профилактическая Медицина. 2013;6:25-34.; Муромцева Г.А., Концевая А.В., Константинов В.В., и др. Распространенность факторов риска неинфекционных заболеваний в Российской популяции в 2012-2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная Терапия и Профилактика. 2014;13(6):4-11. DOI:10.15829/1728-8800-2014-6-4-11.; Catapano A.L., Graham I., De Backer G., et al.; Authors/Task Force Members; Additional Contributor. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):29993058. DOI:10.1016/j.rec.2017.01.002.; Ежов М.В., Сергиенко И.В., Рожкова Т.А., и др. Российские рекомендации по диагностике и лечению семейной гиперхолестеринемии. Атеросклероз и Дислипидемии. 2016;4:21-9.; Montalescot G., Sechtem U., Achenbach S., et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949-3003. DOI:10.1093/eurheartj/eht296.; Touboul P.J., Hennerici M.G., Meairs S., et al. Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis. 2012;34(4):290-6. DOI:10.1159/000343145.; Sakaguchi M., Kitagawa K., Nagai Y., et al. Equivalence of plaque score and intima-media thickness of carotid ultrasonography for predicting severe coronary artery lesion. Ultrasound Med Biol. 2003;29(3):367-71. DOI:10.1016/s0301-5629(02)00743-3.; https://www.rpcardio.com/jour/article/view/2122
-
20Academic Journal
Authors: Dinara I. Sadykova, Liliia F. Galimova, Eugenia S. Slastnikova, Д. И. Садыкова, Л. Ф. Галимова, Е. С. Сластникова
Contributors: Not specified., Отсутствует.
Source: Pediatric pharmacology; Том 17, № 2 (2020); 124-128 ; Педиатрическая фармакология; Том 17, № 2 (2020); 124-128 ; 2500-3089 ; 1727-5776
Subject Terms: критерии, familial hypercholesterolemia, low-density lipoproteins, screening, criteria, семейная гиперхолестеринемия, липопротеины низкой плотности, скрининг
File Description: application/pdf
Relation: https://www.pedpharma.ru/jour/article/view/1836/1142; Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478–3490. doi:10.1093/eurheartj/eht273.; Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH foundation. Inter J Cardiol. 2014;171(3):309–325. doi: 1016/j.ijcard.2013.11.025.; Bays HE, Jones PH, Orringer CE et al. National lipid association annual summary of clinical lipidology 2016. Journal of Clinical Lipidology. 2016;10(1):S1–S43. doi:10.1016/j.jacl.2015.08.002.; Migliara G, Baccolini V, Rosso A, et al. Familial hypercholesterolemia: a systematic review of guidelines on genetic testing and patient management. Frontiers in Public Health. 2017;5:252. doi:10.3389/fpubh.2017.00252.; Ежов М.В., Близнюк С.А., Тмоян Н.А., и др. Регистр пациентов с семейной гиперхолестеринемией и пациентов очень высокого сердечно-сосудистого риска с недостаточной эффективностью проводимой гиполипидемической терапии (РЕНЕССАНС) // Российский кардиологический журнал. — 2019. — Т.24. — №5. — С. 7–13. doi:10.15829/1560-4071-2019-5-7-13.; Садыкова Д.И., Галимова Л.Ф. Семейная гиперхолестеринемия у детей: клинические проявления, диагностика, лечение // Российский вестник перинатологии и педиатрии. — 2017. — Т.62. — №5. — С. 119–123. doi:10.21508/1027–4065–2017–62–5–119–123.; Descamps OS, Tenoutasse S, Stephenne X, et al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis. 2011;218(2):272–280. doi:10.1016/j.atherosclerosis.2011.06.016.; Iughetti L, Predieri B, Balli F, Calandra S. Rational approach to the treatment for heterozygous familial hypercholesterolemia in childhood and adolescence: a review. J Endocrinol Invest. 2007;30(8):700–719. doi:10.1007/BF03347453.; Sorensen KE, Celermajer DS, Georgakopoulos D, et al. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein (a) level. J Clin Invest. 1994;93(1):50–55. doi:10.1172/JCI116983.; Raitakari OT, Juonala M, Kahonen M, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the cardiovascular risk in young Finns study. JAMA. 2003;290(17):2277–2283. doi:10.1001/jama.290.17.2277.; Tonstad S, Joakimsen O, Stensland-Bugge E, et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscler Thromb Vasc Biol. 1996;16(8):984–991. doi:10.1161/01.atv.16.8.984.; Martin AC, Bell DA, Brett T, Watts GF. Beyond cascade screening: detection of familial hypercholesterolaemia at childhood immunization and other strategies. Curr Opin Lipidol. 2017;28(4):321–327. doi:10.1097/MOL.0000000000000423.; Marks D, Thorogood M, Neil Н, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003;168(1):1–14. doi:10.1016/s0021-9150(02)00330-1.; Bell DA, Kirke AB, Barbour R, et al. Can patients be accurately assessed for familial hypercholesterolaemia in primary care? Heart, Lung and Circulation. 2014;23(12):1153–1157. doi:10.1016/j.hlc.2014.06.015.; DeSantes K, Dodge A, Eickhoff J, Peterson AL. Improving universal pediatric lipid screening. J Pediatrics. 2017;188:87–90. doi:10.1016/j.jpeds.2017.05.030.; Groselj U, Kovac J, Sustar U, et al. Universal screening for familial hypercholesterolemia in children: the Slovenian model and literature review. Atherosclerosis. 2018;277:383–391. doi:10.1016/j.atherosclerosis.2018.06.858.; Smith AJ, Turner EL, Kinra S. Universal cholesterol screening in childhood: a systematic review. Academic Pediatrics. 2016;16(8):716–725. doi:10.1016/j.acap.2016.06.005.; Lázaro P, Pérez de Isla L, Watts GF, et al. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia. J Clin Lipidology. 2017;11(1):260–271. doi:10.1016/j.jacl.2017.01.002.; Kerr M, Pears R, Miedzybrodzka Z, et al. Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK. Eur Heart J. 2017;38(23):1832–1839. doi:10.1093/eurheartj/ehx111.; Louter L, Defesche J, Roeters van Lennep J. Cascade screening for familial hypercholesterolemia: practical consequences. Atherosclerosis Supplements. 2017;30:77–85. doi:10.1016/j.atherosclerosissup.2017.05.019.; Datta BN, McDowell IF, Rees A. Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia. Current Opinion in Lipidology. 2010;21(4):366–371. doi:10.1097/mol.0b013e32833c14e2.; Leren TP, Finborud TH, Manshaus TE, et al. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Community Genet. 2008;11(1):26–35. doi:10.1159/000111637.; Клинические рекомендации. «Семейная гиперхолестеринемия.» [Интернет.] — М.: Национальное общество по изучению атеросклероза, 2018. https://noatero.ru/sites/default/files/proekt_klinicheskie_rekomendacii_sghs_mz_rf_18.01.pdf Ссылка активна на 21.05.2020.; Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425–2437. doi:10.1093/eurheartj/ehv157.; Sturm AC, Knowles JW, Gidding SS, et al. Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel. J Am CollCardiol. 2018;72(6):662–680. doi:10.1016/j.jacc.2018.05.044.; De Goma EM, Ahmad ZS, O’Brien EC, et al. Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: data from the CASCADE-FH registry. Circ Cardiovasc Genet. 2016;9(3):240–249. doi:10.1161/CIRCGENETICS.116.001381.; Pe´rez de Isla L, Alonso R, Mata N, et al. Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: insights from the SAFEHEART registry (Spanish familial hypercholesterolaemia cohort study). Arterioscler Thromb Vasc Biol. 2016;36(9):2004–2010. doi:10.1161/ATVBAHA.116.307514.; Kindt I, Mata P, Knowles JW. The role of registries and genetic data-bases in familial hypercholesterolemia. Current Opinionin Lipidology. 2017;28(2):152–160. doi:10.1097/mol.0000000000000398.; https://www.pedpharma.ru/jour/article/view/1836